Related Experiment Videos
Candidate rotavirus vaccine (rhesus rotavirus strain) in children: an evaluation
P F Wright1, T Tajima, J Thompson
1Department of Pediatrics, Vanderbilt University, Nashville, TN 37232.
Insights
An experimental rotavirus vaccine showed 82% effectiveness in children, preventing illness and transmission. Young infants shed more vaccine virus, possibly due to a rapid immune response, indicating promising rotavirus immunoprophylaxis.
Area of Science:
- Pediatrics
- Virology
- Immunology
Background:
- Rotavirus is a major cause of severe enteric illness in children worldwide.
- Development of effective rotavirus vaccines is crucial for public health.
Purpose of the Study:
- To evaluate the effectiveness and safety of an experimental live attenuated rotavirus vaccine (rhesus rotavirus-MMU-18006).
- To assess vaccine virus shedding, serologic response, and clinical outcomes in vaccinated children.
Main Methods:
- Oral administration of live attenuated rotavirus vaccine to 50 children (3 months to 12 years).
- Comparison with 40 concurrently studied control children.
- Monitoring for vaccine virus shedding, serologic response (copro-IgA), and clinical illness.
- Assessment of transmission to control children in a day-care setting.
Main Results:
- 82% of vaccinees showed evidence of vaccine effectiveness (virus shedding or serologic response).
- No clinical rotavirus illness observed in vaccinees compared to controls.
- No transmission of vaccine virus to control children, even with close contact.
- Younger infants (<1 year) shed more vaccine virus, potentially due to a rapid copro-IgA response.
Conclusions:
- The rhesus rotavirus-MMU-18006 vaccine is a promising candidate for rotavirus immunoprophylaxis.
- The vaccine demonstrated safety and effectiveness in preventing rotavirus illness.
- Early immune responses may influence vaccine virus shedding patterns.
Abstract:
Fifty children, 3 months to 12 years of age, were given an experimental, orally administered, live attenuated rotavirus vaccine. Overall evidence of vaccine effectiveness as judged by vaccine virus shedding or a serologic response was seen in 82% of vaccinees. No clinical illness was seen in the rotavirus vaccinees when compared with 40 concurrently studied control children. No transmission to control children was observed even with close daily contact in a day-care setting. Young infants, generally less than 1 year of age, who had not previously experienced wild-type rotavirus infection shed significantly more vaccine virus. Limitation of virus shedding in those already exposed may be related to a prompt copro-IgA response which was significantly elevated by three days after vaccination. In summary, the development of this rotavirus vaccine, rhesus rotavirus-MMU-18006, is a promising step in the development of immunoprophylaxis against this major enteric pathogen.